Valuation: Bioventix PLC

Market Cap 101M 135M 120M 111M 191M 12.65B 195M 1.33B 528M 6.77B 506M 496M 21.32B P/E 2026
11.5x
P/E 2027 * 13.4x
Enterprise Value 95.68M 128M 115M 105M 181M 12.03B 186M 1.26B 503M 6.44B 482M 471M 20.29B EV / Sales 2026
6.24x
EV / Sales 2027 * 7.4x
Free-Float
92.29%
Yield 2026
9.09%
Yield 2027 * 7.79%
1 day-1.28%
1 week-6.10%
Current month-3.75%
1 month+5.48%
3 months+27.48%
6 months+13.24%
Current year+1.05%
1 week 1,850
Extreme 1850
2,097
1 month 1,650
Extreme 1650
2,120
Current year 1,300
Extreme 1300
2,120
1 year 1,300
Extreme 1300
2,255
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
4/28/26 Buy

Chief Financial Officer

66 0.0013%
4/20/26 Free

Chief Executive Officer

9,967 0.1908%
4/20/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%-6.10%-9.41%-46.90% 136M
+2.24%+8.40%+58.47%+69.00% 66.7B
+4.66%+8.90%+16.93%+85.41% 56.88B
-0.60%+1.73%+24.32%+94.40% 56.53B
+2.55%+15.52%+30.43%+120.17% 46.49B
+2.58%+7.89%+32.49%+45.30% 44.8B
+4.09%+6.37%+228.06%+899.75% 41.59B
-0.47%+9.38%+27.53%+52.40% 35.35B
+3.80%-1.00%+98.16%+66.79% 33.29B
+1.48%+6.21%-38.80%+395.73% 25.1B
Average +1.90%+5.36%+46.82%+178.20% 41B
Weighted average by Cap. +2.29%+7.27%+53.72%+181.47%

Financials

2026 2027 *
Net sales 12.5M 16.77M 14.97M 13.77M 23.69M 1.57B 24.28M 165M 65.67M 841M 62.94M 61.59M 2.65B 12.96M 17.39M 15.52M 14.28M 24.56M 1.63B 25.17M 171M 68.08M 872M 65.25M 63.86M 2.75B
Net income 7.1M 9.52M 8.5M 7.82M 13.46M 893M 13.79M 93.58M 37.3M 478M 35.75M 34.98M 1.51B 7.51M 10.07M 8.99M 8.27M 14.22M 944M 14.58M 98.93M 39.43M 505M 37.79M 36.98M 1.59B
Net Debt -4.9M -6.57M -5.87M -5.4M -9.29M -616M -9.52M -64.58M -25.74M -330M -24.67M -24.14M -1.04B -4.62M -6.2M -5.54M -5.1M -8.77M -582M -8.98M -60.96M -24.3M -311M -23.29M -22.79M -981M
Projected Income Statement - Annual - Bioventix PLC
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-11-09 GBX 1,925.00 -1.28% 5,677
26-11-06 GBX 1,950.00 +1.04% 9,698
26-11-05 GBX 1,930.00 -4.69% 157,504
26-11-04 GBX 2,025.00 -1.22% 13,348
26-11-03 GBX 2,050.00 0.00% 15,781
Trader
Investor
-
Global
-
Quality
ESG MSCI
CCC
MarketScreener Ratings - Bioventix PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19.25GBP
Average target price
39.00GBP
Spread / Average Target
+102.60%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Bioventix PLC
  1. Stock Market
  2. Stocks
  3. BVXP Stock